Guidelines for Complications of Cancer Treatment Vol VIII Part B

had undergone surgical procedure including biopsy in 19 andpartial excision in 38 patients. Results: At a median follow-upof 27.5 months, 51 patients have controlled disease. Fourpatients have died of disease progression and 1 patient is alivewith progression yielding 2 and 3 year overall survival of 90%and 85% respectively. Before starting radiotherapy, 30 out of57 patients (53%) had hormone deficiency in at least one axisrequiring replacement. This implies that factors other thanradiotherapy such as tumour and surgery may also beresponsible. Hormone dysfunction was significantly more insellar tumour (27 of 38 patients, 71%; p=0.006) and tumoursclose to PHA (0.001). At baseline, hormone dysfunction wasseen significantly more in GH axis (27 patients, 48%),corticosteroid axis (23 patients, 40%) than thyroid axis (10patients, 17.5%) and sex hormone axes (1 patient, 2%). At 2-and 3-year follow-ups, hormone deficiency in at least 1 axiswas seen in 14/29 patients (48%) and 11/22 patients (50%)respectively. At 2-year follow-up, three patients developedadditional deficiency (1 each in thyroid, steroid and sexhormoneaxis). At 3-year follow-up, only 1 more patient (14%)developed additional deficiency. Conclusions: More than halfof patients with low-grade brain tumours before radiotherapyhad hormone deficiency in at least one axis, with maximumdeficiency seen in sellar tumours. Hormone dysfunction wasseen in a very small number of patients at 2- and 3-year followupsin this cohort of patients treated with SCRT. Validation ofthese encouraging results will come from maturation of datain a larger number of patients at a longer follow-up.C. Vascular events1. Cerebrovascular mortality in patients with pituitaryadenoma.Brada M, Ashley S, Ford D, Traish D, Burchell L, Rajan B.Clin Endocrinol (Oxf). 2002;57(6):713-7.364